Table 2 Secondary objectives

To determine the effects of 12 weeks’ ASV in patients with SDB early after AMI on the following:

- Infarct size

- Left ventricular remodelling assessed using CMR (myocardial salvage, microvascular obstruction, change of infarct size, infarct size at 12 weeks, change in left ventricular ejection fraction, left ventricular end-systolic volume, left ventricular end-diastolic volume)

- NT-proBNP levels

- Disease-specific symptom burden (Seattle Angina Questionnaire)

- Daytime and night time blood pressure and heart rate

- Total cholesterol and low-density lipoprotein cholesterol

- SDB (apnoeas and hypopnoeas per hour of sleep, mean oxygen saturation)

- Renal function (GFR, calculated using the 4v-MDRD formula)

- Biochemical markers of inflammation and vascular function (hsCRP, blood count, fibrinogen)